# **ORGENTEC Diagnostika GmbH**


Carl-Zeiss-Straße 49-51 55129 Mainz - Germany

Phone: +49 (0) 61 31 / 92 58-0 Fax: +49 (0) 61 31 / 92 58-58

Internet: www.orgentec.com



Electronic Instruction For Use: version



# ORG 240A Anti-Tissue-Transglutaminase IgA

### INTENDED PURPOSE

Anti-Tissue-Transglutaminase IgA is an ELISA-based test system for the quantitative measurement of IgA class autoantibodies against tissue transglutaminase (tTG) in human serum or plasma samples. This product is intended for professional in vitro diagnostic use only.

Autoantibodies against tissue transglutaminase (tTG) during a gluten containing diet are the most obvious serologic feature of coeliac disease (CD). Determination of serum levels of IgA against tTG is the first choice in suspected CD. In subjects with either primary or secondary humoral IgA deficiency, at least one additional test measuring IgG class CD-specific antibodies is recommended. The clinical relevance of a positive anti-tTG result should be confirmed by histology of the small intestinal mucosa.

ALEGRIA TEST STRIPS

WASH

SYSTEM FLUID

Alegria® Test Strips

Wash Buffer

System Fluid

Ready to use

## SYMBOLS USED

In vitro diagnostic medical device

Manufacturer

REF Catalogue number

Sufficient for ... determinations

LOT Batch code

Use by

Temperature limitation

Consult instructions for use

Keep away from sunlight

Do not reuse

Date of manufacture

CE marked according to 98/79/EC

240A\_3 Electronic Instruction For Use: version

## PRINCIPLE OF THE TEST

Human recombinant tissue transglutaminase is bound to microwells.

The Alegria® assay features barcoded 8-well-microstrips, called Alegria® Test Strips. Each strip is designed for a single determination of one patient sample. The Alegria® Test Strip holds a complete set of reagents. Included are enzyme conjugate, enzyme substrate, sample buffer and a test specific control. Furthermore each strip has two antigen-coated wells which serve as reaction wells for one control and one patient sample.

The determination is based on an indirect enzyme linked immune reaction with the following steps: Antibodies present in positive samples bind to the antigen coated on the surface of the two reaction wells forming an antibody antigen complex. After incubation, a first washing step removes unbound and unspecific bound molecules. Subsequently added enzyme conjugate binds to the immobilized antibody-antigen complex. After incubation, a second washing step removes unbound enzyme conjugate. Addition of enzyme substrate solution results in hydrolisation and color development during incubation. The intensity of the blue color correlates with the concentration of the antibody-antigen-complex and can be measured photometrically at 650 nm.

The Alegria® Test Strip is based on the proprietary SMC®-Technology (Sensotronic Memorized Calibration): information about the assay, analysis and evaluation, and the lot-specific expiry date is contained on the barcode printed on each Alegria® Test Strip.

The Alegria® Test Strip can be used with the diagnostic instruments Alegria® and Alegria® 2. By means of SMC®-Technology data encoded on the barcode are transferred from the Alegria® Test Strip to the instrument and the assay is automatically processed and evaluated. The instrument reads the date of expiry and rejects further processing if the Alegria® Test Strip is out of date.

# WARNINGS AND PRECAUTIONS

- All reagents of this kit are intended for professional in vitro diagnostic use only.
- Components containing human serum were tested and found negative for HBsAg, HCV, HIV1 and HIV2 by FDA approved methods. No test can guarantee the absence of HBsAg, HCV, HIV1 or HIV2, and so all human serum based reagents in this kit must be handled as though capable of transmitting infection.
- · Bovine serum albumin (BSA) used in components has been tested for BSE and found negative.
- Avoid contact with the substrate TMB (3,3',5,5'-Tetramethyl-benzidine).
- Stop solution contains acid, classifiaction is non-hazardous. Avoid contact with skin.
- Control, sample buffer and wash buffer contain sodium azide 0.09% as preservative. This concentration is classified as non-hazardous.
- Enzyme conjugate contains ProClin 300 0.05% as preservative. This concentration is classified as non-hazardous.
- During handling of all reagents, controls and serum samples observe the existing regulations for laboratory safety regulations and good laboratory practice:
- First aid measures: In case of skin contact, immediately wash thoroughly with water and soap. Remove
  contaminated clothing and shoes and wash before reuse. If system fluid comes into contact with skin,
  wash thoroughly with water. After contact with the eyes carefully rinse the opened eye with running
  water for at least 10 minutes. Get medical attention if necessary.
- Personal precautions, protective equipment and emergency procedures:

Observe laboratory safety regulations. Avoid contact with skin and eyes. Do not swallow. Do not pipette by mouth. Do not eat, drink, smoke or apply makeup in areas where specimens or kit reagents are handled. When spilled, absorb with an inert material and put the spilled material in an appropriate waste disposal.

- Exposure controls / personal protection: Wear protective gloves of nitril rubber or natural latex.
  Wear protective glasses. Used according to intended use no dangerous reactions known.
- Conditions to avoid: Since substrate solution is light-sensitive. Store in the dark.
- · For disposal of laboratory waste the national or regional legislation has to be observed.

Observe the guidelines for performing quality control in medical laboratories by assaying control sera.

### CONTENTS OF THE KIT

₹ 24 ORG 240A-24 ALEGRIA TEST STRIPS 24

Sufficient for 24 determinations

Alegria® Test Strips are modules of 8 wells each composed of:

Wells 1 + 2: empty and not coated (wells for the sample dilution)

Wells 3 + 4: coated with antigen (reaction wells)

Well 5: Control; yellow; containing test specific antibodies, PBS, BSA, detergent, preservative sodium azide 0.09%.

Well 6: Enzyme Conjugate; light red; containing anti-human IgA antibodies,

HRP labelled; PBS, BSA, detergent, preservative ProClin 0.05%.

Well 7: Sample Buffer: yellow; containing PBS, BSA, detergent, preservative

sodium azide 0.09%.

Well 8: **TMB Substrate**: clear; containing 3,3', 5,5'- Tetramethylbenzidin.

Text on Test Strip: tTG lgA on printout: tTG-lgA

1x 20 ml Wash Buffer, containing Tris, detergent, preservative sodium azide 0.09%; 50 x conc.

SYSTEM FLUID

1x 2.5 ml System Fluid, contains acid: 1000 x concentrate

# STORAGE AND STABILITY

- · Store test kit at 2-8°C in the dark.
- Do not expose reagents to heat, sun, or strong light during storage and usage.
- Store Alegria® Test Strips sealed and dessicated in the clip bag provided.
- Shelf life of the unopended test kit is 15 months from day of production.
   Unopened reagents are stable until expiration of the kit. See labels for individual batch.
- Diluted Wash Buffer and System Fluid are stable for at least 30 days when stored at 2-8°C.
   Once transferred to the reagent container we recommend consumption on the same day.

#### MATERIALS REQUIRED

- Vortex mixer
- Pipettes
- · Measuring cylinder for 1000 ml and 2500 ml
- · Distilled or deionized water

# SPECIMEN COLLECTION, STORAGE AND HANDLING

- Collect whole blood specimens using acceptable medical techniques to avoid hemolysis.
- Allow blood to clot and separate the serum or plasma by centrifugation.
- Test serum should be clear and non-hemolyzed. Contamination by hemolysis or lipemia should be avoided, but does not interfere with this assay.
- Specimens may be refrigerated at 2-8°C for up to five days or stored at -20°C up to six months.
- Avoid repetitive freezing and thawing of serum or plasma samples. This may result in variable loss of antibody activity.
- · Testing of heat-inactivated sera is not recommended.
- Sample volume needed per assay: 10 μl

# **PROCEDURAL NOTES**

- Do not use kit components beyond their expiration dates.
- All materials must be at room temperature (20-28°C) prior to use.
- · To avoid carryover or contamination, change the pipette tip between samples when pipetting manually.

#### PREPARATION OF REAGENTS



Dilute the content of the Wash Buffer concentrate (50x) with distilled or deionized water to a final volume of 1000 ml prior to use. Transfer the diluted Wash Buffer into the instrument reagent container. If only one Alegria run is to be performed on one day we recommend transferring only 500 ml diluted Wash Buffer.

### SYSTEM FLUID

Dilute the content of the System Fluid concentrate (1000x) with distilled or deionized water to a final volume of 2500 ml prior to use. Transfer the diluted System Fluid into the instrument reagent container.

#### ALEGRIA TEST STRIPS

Take the required number of Alegria® Test Strips out of the clip bag and let them reach room temperature (20-28° C).

#### TEST PROCEDURE

The fully automated random access analysers of the Alegria® family use Alegria® Test Strips with SMC® technology.

### Alegria®

(1) Remove the foil from the empty wells 1 to 4 of the Alegria® Test Strip.

Do not remove foil with printed barcode, covering wells 5 to 8.

- (2) Pipette 10 µl undiluted sample at the bottom of well 1.
- (3) Insert the strip into the SysTray.
- (4) Place loaded SysTrays into the correct position in the Alegria® instrument and start run. All further steps will be done automatically. The test run is completed when the instrument starts printing the results.

### Alegria® 2:

Insert Test Strips in Strip Tray and insert sample tubes in sample rack, as described in the Alegria® 2 User Manual.

Detailed information on how to load the instruments with Test Strips and other reagents and how to operate the instruments can be found in the respective user manuals.

- Alegria<sup>®</sup> User Manual
- Alegria<sup>®</sup> 2 User Manual

#### **CALIBRATION**

This assay system is calibrated in relative arbitrary units, since no international reference preparation is available for this assay.

# **CALCULATION OF RESULTS**

By means of SMC® Technology (Sensotronic Memorized Calibration), all test data are transferred to the system through individual barcodes on the Alegria® Test Strip. Calculation and interpretation of results will be performed automatically.

### PERFORMANCE CHARACTERISTICS

# Measuring range

The calculation range of this Alegria<sup>®</sup> assay is 0 - 200 U/ml

#### **Expected values**

In a normal range study with samples from healthy blood donors the following ranges have been established with this Alegria® assay: Cut-off 10 U/ml

# Interpretation of results

Normal: < 10 U/ml Elevated: ≥ 10 U/ml

### Linearity

Three patient samples containing high levels of specific antibody were serially diluted in sample buffer to demonstrate the dynamic range of the assay. Activity for each dilution was calculated by means of SMC® Technology.

Sample	Dilution	Observed	Expected	O/E
		U/ml	U/ml	[%]
1	1:100	124.1	124.1	100
	1:200	1:200 64.7 62.1		104
	1:400	30.8	31.0	99
	1:800	1:800 16.7 15.5		108
2	1:100	98.6	98.6	100
	1:200	50.6	49.3	103
	1:400	26.1	24.7	106
	1:800	13.9 12.3		113
3	1:100	74.9	74.9	100
	1:200	38.7 37.5		103
	1:400	18.6 18.7		99
	1:800	9.6	9.4	103

### Sensitivity

Functional sensitivity was determined to be: 1 U/ml

The smallest amount of analyte detectable is:

### Reproducibility

Intra-assay precision: Coefficient of variation (CV) was calculated for each of three samples from the results of 24 determinations in a single run. Results for precision-within-assay are shown in the table below.

Inter-assay precision: Coefficient of variation (CV) was calculated for each of three samples from the results of 6 determinations in 5 different runs. Results for run-to-run precision are shown in the table below.

Intra-Assay				
Sample	Mean			
	U/ml	% CV		
1	19.4	8.5		
2	107.4	6.7		
3	177.9	6.5		

Inter-Assay				
Sample	Mean			
	U/ml	% CV		
1	18.9	6.6		
2	104.1	7.9		
3	176.0	5.5		

#### Interfering substances

No interference has been observed with haemolytic (up to 1000 mg/dl) or lipemic (up to 3 g/dl triglycerides) sera or plasma, or bilirubin (up to 40 mg/dl) containing sera or plasma. Nor have any interfering effects been observed with the use of anticoagulants (Citrate, EDTA, Heparine). However for practical reasons it is recommended that grossly hemolyzed or lipemic samples should be avoided.

# Study results

Study population				<u>n</u>	n pos	<u>%</u>	
Coeliac disease				35	35	100.0	
Normal human sera				90	3	3.3	
			Clinical Diagnosis				
			Pos	N	eg		
ORG 2	40A	Pos	35		3		

Anti-Tissue-Transglutaminase IgA Neg 0 87 35 90

Sensitivity: 100.0 %

125

Specificity: 96.7 % Overall agreement: 97.6 %

# Correlation Alegria® versus Alegria® 2

45 samples have been tested in paralell with Alegria and Alegria and Alegria accordation of R<sup>2</sup>=97.0 %

#### LIMITATIONS OF THE PROCEDURE

This assay is a diagnostic aid. A definite clinical diagnosis should not be based on the results of a single test, but should be made by the physician after all clinical and laboratory findings have been evaluated concerning the entire clinical picture of the patient. Also every decision for therapy should be taken individually. The above pathological and normal reference ranges for antibodies in patient samples should be regarded as recommendations only. Each laboratory should establishe its own ranges according to ISO 15189 or other applicable laboratory guidelines.

#### REFERENCES

- Alessio M, Tonutti E, Brusca I, Radice A, Licini L, Sonzogni A, Florena A, Schiaffino E, Marus W, Sulfaro S, Villalta D: Correlation between IgA tissue transglutaminase antibody ratio and histological finding in celiac disease: A multicentre study. J Pediatr. Gastroenterol. Nutr. 2011.
- Cummins AG, Roberts-Thomson IC: Prevalence of celiac disease in the Asia-Pacific region. J Gastroenterol. Hepatol. 2009. 24:1347-1351.
- Giersiepen K, Lelgemann M, Stuhldreher N, Ronfani L, Husby S, Koletzko S, Korponay-Szabo IR: Accuracy of diagnostic antibody tests for coeliac disease in children: summary of an evidence report. J Pediatr. Gastroenterol. Nutr. 2012, 54:229-241.
- 4. Green PH, Cellier C: Celiac disease. N. Engl. J Med. 2007, 357:1731-1743.
- Gupta R, Reddy DN, Makharia GK, Sood A, Ramakrishna BS, Yachha SK, Thapa BR, Banerjee R, Anuradha S, Dutta U, Puri AS, Jain AK, Mulder CJ, Kumar A, Boindala S: Indian task force for celiac disease: current status. World J Gastroenterol. 2009, 15:6028-6033.
- Husby S, Koletzko S, Korponay-Szabo IR, Mearin ML, Phillips A, Shamir R, Troncone R, Giersiepen K, Branski D, Catassi C, Lelgeman M, Maki M, Ribes-Koninckx C, Ventura A, Zimmer KP: European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr. Gastroenterol. Nutr. 2012, 54:136-160.
- Mahadov S, Green PH: Celiac disease: a challenge for all physicians. Gastroenterol. Hepatol.(N Y) 2011, 7:554

   -556
- 8. Marietta EV, Rashtak S, Murray JA: Correlation analysis of celiac sprue tissue transglutaminase and deamidated gliadin IgG/IgA. World J Gastroenterol. 2009, 15:845-848.
- 9. Murray JA: Serodiagnosis of celiac disease. Clin. Lab. Med. 1997, 17:445-464.
- 10. Rubio-Tapia A, Murray JA: Celiac disease. Curr. Opin. Gastroenterol. 2010, 26:116-122.
- 11. Telega G, Bennet TR, Werlin S: Emerging new clinical patterns in the presentation of celiac disease. Arch. Pediatr. Adolesc. Med 2008, 162:164-168.
- 12. Tjon JM, van BJ, Koning F: Celiac disease: how complicated can it get? Immunogenetics 2010, 62:641-651.
- 13. van der Windt DA, Jellema P, Mulder CJ, Kneepkens CM, van der Horst HE: Diagnostic testing for celiac disease among patients with abdominal symptoms: a systematic review. JAMA 2010, 303:1738-1746.

14. Villalta D, Tonutti E, Prause C, Koletzko S, Uhlig HH, Vermeersch P, Bossuyt X, Stern M, Laass MW, Ellis JH, Ciclitira PJ, Richter T, Daehnrich C, Schlumberger W, Mothes T: IgG antibodies against deamidated gliadin peptides for diagnosis of celiac disease in patients with IgA deficiency. Clin. Chem. 2010, 56:464-468.

Notice to the user (European Union):

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the EU Member State in which the user and/or the patient is established.

Change Control

Former version: ORG 240A\_IFU\_EN\_QM113096\_2018-01-02\_2 Reason for revision: Inclusion of Alegria® 2